← Leaderboards
Eben L Rosenthal
University Of Alabama At Birmingham
$10,844,750
Attributed
$13,257,347
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,632,347 · 13
FDA$1,625,000 · 1
By mechanism
R01$11,513,539 · 7
R21$1,017,594 · 3
K08$559,674 · 1
R03$143,540 · 1
R13$23,000 · 2
Top collaborators
- Gordon Li5 shared
- Eric J Sorscher4 shared
- Frederick T Chin1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Christopher Anthony Girkin$5,288,797
- Massimo Antonio Fazio$2,153,687
- Jason Morgan Warram$3,373,796
- Bharat Panuganti$187,440
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorAntibodiesHead And Neck CancerOperative Surgical ProceduresIn VivoMalignant NeoplasmsEpidermal Growth Factor ReceptorExcisionLabelTissuesImagePanitumumabHead And Neck Squamous Cell CarcinomaFluorescenceSurgeonNeoplasm MetastasisSensitivity And SpecificityMolecularDetectionPrimary NeoplasmContrast MediaSpecificityImage-Guided SurgeryClinical Trials
Grant awards (43)
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer$449,010
R01 · FY2025 · CA · contact PI
Secondary Molecular Imaging (SMI) for head and neck cancer$381,676
R01 · FY2025 · CA · contact PI
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer$447,763
R01 · FY2024 · CA · contact PI
Secondary Molecular Imaging (SMI) for head and neck cancer$338,740
R01 · FY2024 · CA · contact PI
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors$508,841
R01 · FY2023 · CA
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer$452,685
R01 · FY2023 · CA · contact PI
American Head and Neck International Conference$8,000
R13 · FY2023 · DE · contact PI
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors$508,841
R01 · FY2022 · CA
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer$426,011
R01 · FY2022 · CA · contact PI
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors$613,821
R01 · FY2021 · CA
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2021 · FD
Next Generation Sentinel Node Mapping$275,230
R01 · FY2021 · CA · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$125,000
R01 · FY2021 · FD
Next Generation Sentinel Node Mapping$49,106
R01 · FY2021 · CA · contact PI
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors$615,738
R01 · FY2020 · CA · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2020 · FD
Next Generation Sentinel Node Mapping$326,765
R01 · FY2020 · CA · contact PI
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors$626,189
R01 · FY2019 · CA · contact PI
Prototype optical device for image guided surgery with panitumumab-IRDye800$420,094
R01 · FY2019 · CA · contact PI
Prototype optical device for image guided surgery with panitumumab-IRDye800$573,830
R01 · FY2018 · CA · contact PI
Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)$500,000
R01 · FY2018 · FD
Prototype optical device for image guided surgery with panitumumab-IRDye800$584,950
R01 · FY2017 · CA · contact PI
Prototype optical device for image guided surgery with panitumumab-IRDye800$485,292
R01 · FY2016 · CA · contact PI
Prototype optical device for image guided surgery with panitumumab-IRDye800$492,724
R01 · FY2015 · CA · contact PI
Imaging Guided Surgery using Fluorescently Labeled Cetuximab$268,136
R21 · FY2014 · CA · contact PI
CD147 as a Novel Target in Head and Neck Cancer$257,421
R01 · FY2014 · CA · contact PI
Optical imaging of primary and regional melanoma to guide surgical resection$155,067
R21 · FY2014 · CA · contact PI
CD147 as a Novel Target in Head and Neck Cancer$249,459
R01 · FY2013 · CA · contact PI
Optical imaging of primary and regional melanoma to guide surgical resection$191,672
R21 · FY2013 · CA · contact PI
CD147 as a Novel Target in Head and Neck Cancer$265,382
R01 · FY2012 · CA · contact PI
8th Annual Conference on Head and Neck Cancer$15,000
R13 · FY2012 · DE · contact PI
CD147 as a Novel Target in Head and Neck Cancer$265,382
R01 · FY2011 · CA · contact PI
CD147 as a Novel Target in Head and Neck Cancer$273,589
R01 · FY2010 · CA · contact PI
Fluorescently Labeled Anti-EGFR to Guide Removal of Lymph Node Metastasis$219,750
R21 · FY2010 · DE · contact PI
Fluorescently Labeled Anti-EGFR to Guide Removal of Lymph Node Metastasis$182,969
R21 · FY2009 · DE · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$97,972
K08 · FY2009 · CA · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$88,366
K08 · FY2009 · CA · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$96,062
K08 · FY2008 · CA · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$94,207
K08 · FY2007 · CA · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$92,407
K08 · FY2006 · CA · contact PI
Role of Fibroblast-Derived MT1-MMP in Oral Cancer$71,040
R03 · FY2006 · DE · contact PI
Tumor Stromal Interactions in Head and Neck Cancer$90,660
K08 · FY2005 · CA
Role of Fibroblast-Derived MT1-MMP in Oral Cancer$72,500
R03 · FY2005 · DE